Company performance
Add to research
Current Price
as of Jun 20, 2025$23.60
P/E Ratio
N/A
Market Cap
$1.4B
Description
Add to research
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerJANX
- Price$23.6+3.87%
Trading Information
- Market cap$1.40B
- Float83.71%
- Average Daily Volume (1m)831,010
- Average Daily Volume (3m)971,507
- EPS-$1.36
Company
- Revenue$9.34M
- Rev growth (1yr)-100.00%
- Net income-$23.51M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$34.38M
- EV$676.84M
- EV/Revenue72.50
- P/EN/A
- P/S156.20
- P/B1.38
- Debt/Equity2.23
Documents
Add to research
SEC Filings